JDRF Northern California Center of Excellence - Northern California Center of Excellence

Covid-19 information

Our Mission

Center of Excellence: A center of excellence (COE) brings together people from different disciplines and provides shared facilities/resources

JDRF Centers of Excellence are intended to support Universities and/or Research Institutes that have a track record of excellence in T1D research to develop and pursue collaborative research programs that drive towards translational outcomes and clinical impact and are aligned with JDRF Research goals.

Greater Bay Area Chapter to Honor Co-Directors of the JDRF Northern California Center of Excellence

February 4th, 2020

On Saturday, May 16, 2020, the JDRF Greater Bay Area Chapter will host the 22nd Annual Hope Gala, bringing prominent business leaders and families from around the Bay Area to The Ritz-Carlton, San Francisco for an evening of fundraising, celebration, and networking.

JDRF Launches Northern California Center of Excellence to Accelerate Breakthroughs to Cure T1D

September 4th, 2019

JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced the launch of the JDRF Northern California Center of Excellence, to accelerate high-impact research at Stanford University and the University of California, San Francisco, to develop cures for T1D.

Kickoff Symposium

October 7, 2019, 9:30am - 4:00pm

UCSF Aldea Center CoE Kickoff symposium agenda

Faculty Profile: Everett Meyer, MD

Assistant Professor, Medicine - Med/Blood and Marrow Transplantation, Stanford University

Dr. Meyer has a focus on the study of human immune tolerance in the hematopoietic stem cell setting and islet cell transplantation. He studies murine pre-clinical models with a focus on T cell immunotherapy, T regulatory cell and invariant NKT cell biology and non-myeloblative hematopoietic stem cell transplantation for tolerance induction. In established collaborations with Dr. Seung Kim, Dr. Meyer has developed genetic engineering to reprogram Tregulatory cells to target them to mouse islet allografts and human islet xenografts. This approach has resulted in some startling discoveries: (1) genetically engineered Tregulatory cells producing Chimeric Antigen Receptor (CAR) are much better at preventing islet graft rejection than normal Tregulatory cells and (2) genetically engineered Tregulatory cells can alter the immune system to create new immune memory and tolerance.